Colgate Palmolive (India) share price & results

Colgate Palmolive (India) Limited· Fast Moving Consumer Goods

Results to: Sept 2026
Latest analysed call: Q1 FY27
Ownership as of: Sept 2026

Indian subsidiary of Colgate-Palmolive; makes Colgate oral-care and Palmolive personal-care products.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	1,706 ₹ crore	+12.2% YoY	Quarterly, as filed	Quarter to Sept 2026	Revenue from operations as filed.
Operating margin	28.0 %	−3.0 pts YoY	Operating profit / revenue	Quarter to Sept 2026	For the quarter; a change is in percentage points.
Net profit	342 ₹ crore	+4.3% YoY	Quarterly, as filed	Quarter to Sept 2026	Profit after tax as filed.
Return on equity	Unavailable	+44.2 ptsFY Mar 2009 vs FY Mar 2008	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.
Free cash flow margin	Unavailable	+0.4 ptsFY Mar 2010 vs FY Mar 2009	Fiscal year	FY · period unavailable	Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)	Unavailable	−0.1 ptsFY Mar 2010 vs FY Mar 2009	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

3 of 6 judged targets kept · 7 open · verdicts reflect calls analysed to Q1 FY27.

Colgate Palmolive (India) Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (3 achieved, 3 missed, 7 open).

Target	Original wording	Said	Latest call	Verdict
Premiumization growth rate vs rest of portfolio	4x Call transcript, Q4 FY25 · 22 May 2025	Q4 FY25	Q1 FY27:Management confirms the premium business is growing 5X-6X faster than competitors and the market, continuing to exceed the original 4x target. Call transcript, Q1 FY27 · 17 Aug 2026	Achieved
EBITDA Margin Band	32% to 34% range Call transcript, Q4 FY25 · 22 May 2025	Q4 FY25	Q1 FY27:The promise period for FY26 has concluded. The final reported EBITDA margin for FY26 was 31.2%, which is below the targeted 32-34% range. Call transcript, Q1 FY27 · 17 Aug 2026	Missed
EBITDA Margin	around 30-32% over the next two quarters Call transcript, Q4 FY26 · 28 May 2026	Q4 FY26	Q1 FY27:Management walked back the guidance, stating 'in the short term, we're not going to, you know, be held by the EBITDA levels, no target at a specific level' due to a strategic decision to increase advertising spend. Call transcript, Q1 FY27 · 17 Aug 2026	Revised Down

Source: Inve Guidance Tracker for Colgate Palmolive (India) Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Colgate Palmolive (India) Limited's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.

See the full record

Price

₹1,603.4 −0.75% · −₹12.1

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −28.4% 1Y

1Y: ₹2,239.4 on 24 Oct 2025 → ₹1,603.4. High ₹2,295.3 (26 Feb 2026), low ₹1,603.4 (27 Oct 2026).

Previous close: ₹1,615.5
Market cap: ₹43.6k Cr
52-week range: ₹1,603.4 – ₹2,295.3
One year: −27.66%

Overview

Symbol: NSE:COLPAL
Sector: Fast Moving Consumer Goods
Exchange: NSE
Currency: INR

What Colgate Palmolive (India) Limited does

Based on the company's own presentations, annual report and earnings calls.

Colgate-Palmolive (India) Limited is the Indian affiliate of the US-based Colgate-Palmolive Company, manufacturing and marketing oral care, personal care and home care products under the Colgate and Palmolive brands. It earns primarily by selling toothpaste, toothbrushes and mouthwash under Colgate, complemented by a Palmolive personal-care range, through a nationwide retail and stockist network. Products are made at four company-owned manufacturing plants plus third-party manufacturing sites across India, and distributed via a large on-ground sales team reaching millions of retail outlets directly. The company has operated in India for over 87 years and is headquartered in Mumbai.

Segments

Oral Care
Personal Care
Home Care

Manufacturing plants: 4 owned plants — Goa, Baddi (Himachal Pradesh), Sri City (Andhra Pradesh) and Sanand (Gujarat) — plus third-party manufacturing sites across India
Retail outlets reached directly: Over 1.7 million outlets
On-ground sales/distribution team: 5,000+ individuals driving retail presence
Corporate headquarters: Mumbai
Combined manufacturing plant area: 3,64,600 sq. m across the four owned plants
Core brand portfolio: Colgate (oral care) and Palmolive (personal care)

Headquarters Mumbai, India Company website

How the price took the results

close before → close after

Q1 FY27: −0.9%; 17 Aug
Q4 FY26: −1.3%; 28 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Guidance

What management said, and what became of it

3 of 6 judged targets kept · 7 open · verdicts reflect calls analysed to Q1 FY27.

Colgate Palmolive (India) Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (3 achieved, 3 missed, 7 open).

Target	Original wording	Said	Latest call	Verdict
Premiumization growth rate vs rest of portfolio	4x Call transcript, Q4 FY25 · 22 May 2025	Q4 FY25	Q1 FY27:Management confirms the premium business is growing 5X-6X faster than competitors and the market, continuing to exceed the original 4x target. Call transcript, Q1 FY27 · 17 Aug 2026	Achieved
EBITDA Margin Band	32% to 34% range Call transcript, Q4 FY25 · 22 May 2025	Q4 FY25	Q1 FY27:The promise period for FY26 has concluded. The final reported EBITDA margin for FY26 was 31.2%, which is below the targeted 32-34% range. Call transcript, Q1 FY27 · 17 Aug 2026	Missed
EBITDA Margin	around 30-32% over the next two quarters Call transcript, Q4 FY26 · 28 May 2026	Q4 FY26	Q1 FY27:Management walked back the guidance, stating 'in the short term, we're not going to, you know, be held by the EBITDA levels, no target at a specific level' due to a strategic decision to increase advertising spend. Call transcript, Q1 FY27 · 17 Aug 2026	Revised Down

Source: Inve Guidance Tracker for Colgate Palmolive (India) Limited · to Q1 FY27

The full ledger

Open Colgate Palmolive (India) Limited’s full ledger

A free account opens 5 company ledgers a month. All 13 tracked commitments, with each call’s wording and source.

Browse the register

Latest analysed call: Q1 FY27, 17 Aug 2026. 3 calls analysed.

No analysed call after Q1 FY27, though results run to Sept 2026.

Call summaries

Q1 FY27 — 17 Aug 2026

Colgate Palmolive (India) Limited Q1 FY27

Colgate Palmolive (India) Limited delivered a strong Q1 FY27, marked by double-digit growth in sales and profitability, driven by a strategic focus on premiumization and increased advertising investments. The company maintained robust gross margins through operational efficiencies and is actively working to grow the oral care category and revitalize its personal care segment through a new partnership. Management expressed confidence in its balanced growth model while closely monitoring macro-economic factors.

Read the full call

Q4 FY26 — 28 May 2026

Colgate-Palmoliv Q4 FY26

Colgate-Palmolive (India) Limited reported a strong Q4 FY26 with accelerated net sales growth of 9% and domestic growth of 9.2%, driven by premiumization and core brand strength. Gross and EBITDA margins remained robust, with Q4 NPAT at ₹353 crores. While the full year saw flat top-line growth, the company is optimistic about future growth, focusing on balanced volume and pricing, and addressing challenges like the GST IDS impact and high promotional intensity.

Read the full call

Q4 FY25 — 22 May 2025

Colgate-Palmoliv Q4 FY25

Colgate-Palmolive (India) Limited reported a robust 6.3% top-line growth for FY25, reaching ₹5,999 crores, underpinned by strong margins and increased brand investments. While Q4 FY25 saw a 1.9% top-line decline and flat volume due to soft urban demand and high competitive intensity in trade, management expects a sequential recovery in the latter half of the year, driven by premiumization and rural resilience.

Read the full call

Summaries of each call, in Inve’s own words; the transcript is not reproduced. Not investment advice.

Every analysed call

Colgate Palmolive (India) Limited earnings calls (COLPAL)

Fundamentals

Ratios, each with its period

Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2006 to Mar 2010).

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
2.00 days 3.00 days 2.00 days 2.00 days 2.00 days

How it is calculated. Reported receivable days from the annual accounts.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
56.00 days 51.00 days 53.00 days 48.00 days 54.00 days

How it is calculated. Reported inventory days, using material cost / cost of goods sold.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
176.00 days 174.00 days 187.00 days 193.00 days 177.00 days

How it is calculated. Reported payable days, using material cost / cost of goods sold.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
-119.00 days -120.00 days -132.00 days -143.00 days -122.00 days

How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
-42.00 days -51.00 days -76.00 days -72.00 days -58.00 days

How it is calculated. Reported net working capital days from the annual accounts.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
73.00% 87.00% 75.00% 71.00% 63.00%

How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
— — — — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
2.00 days	3.00 days	2.00 days	2.00 days	2.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
56.00 days	51.00 days	53.00 days	48.00 days	54.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
176.00 days	174.00 days	187.00 days	193.00 days	177.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
-119.00 days	-120.00 days	-132.00 days	-143.00 days	-122.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
-42.00 days	-51.00 days	-76.00 days	-72.00 days	-58.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
73.00%	87.00%	75.00%	71.00%	63.00%

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
—	—	—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

What the filings say

Net profit, year on year: +4% (quarter to sept 2026 against sept 2025).

In ₹ crore. Oldest period first.

Line item	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026	Sept 2026
Sales	1,462	1,463	1,434	1,520	1,486	1,595	1,603	1,706
Expenses	1,007	964	981	1,054	1,044	1,086	1,120	1,232
Operating profit	454	498	453	465	442	510	483	473
Operating margin	31.0%	34.0%	32.0%	31.0%	30.0%	32.0%	30.0%	28.0%
Other income	20	19	18	15	31	0	19	22
Interest	1	1	1	1	1	1	1	1
Depreciation	41	38	38	37	36	35	39	34
Profit before tax	433	478	432	442	436	474	462	460
Tax rate	25.0%	26.0%	26.0%	26.0%	26.0%	25.0%	26.0%	26.0%
Net profit	323	355	321	328	324	353	343	342
EPS (₹ per share)	11.87	13.05	11.79	12.04	11.91	12.99	12.61	12.56

Source: Inve data · income statement, quarterly · to Sept 2026

In ₹ crore. Oldest period first.

Line item	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	5,226	5,681	6,041	6,035
Expenses	3,679	3,780	4,081	4,165
Operating profit	1,547	1,900	1,957	1,870
Other income	41	57	138	64
Interest	4	5	4	4
Depreciation	175	171	163	146
Profit before tax	1,409	1,781	1,930	1,784
Net profit	1,047	1,324	1,437	1,326

Source: Inve data · income statement, annual · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2023	Mar 2024	Mar 2025	Sept 2025	Mar 2026	Sept 2026
Equity capital	27	27	27	27	27	27
Reserves	1,689	1,847	1,637	1,555	1,557	1,590
Borrowings	69	72	61	60	47	49
Other liabilities	1,098	1,250	1,293	1,535	1,777	1,971
Total liabilities	2,883	3,197	3,019	3,178	3,408	3,638
Fixed assets	862	794	776	742	718	673
Capital work in progress	114	110	38	29	27	52
Investments	0	0	0	0	0	0
Other assets	1,907	2,292	2,204	2,406	2,663	2,913
Total assets	2,883	3,197	3,019	3,178	3,408	3,638

Source: Inve data · balance sheet · to Sept 2026

In ₹ crore. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operations	784	1,626	1,176	1,199	1,394	1,806
Cash from investing	71	-108	-8	79	56	374
Cash from financing	-956	-1,091	-1,087	-1,195	-1,671	-1,422
Net cash flow	-101	427	82	83	-221	758
Free cash flow	727	1,576	1,107	1,123	1,323	1,730

Source: Inve data · cash flow · to Mar 2026

In days and %. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	9	16	11	11	14	13
Inventory days	79	78	68	63	76	75
Days payable	179	169	155	187	185	275
Cash conversion cycle	-91	-75	-76	-113	-95	-188
Working capital days	-84	-25	-32	-46	-37	-59
Return on capital employed	92.0%	92.0%	79.0%	97.0%	105.0%	108.0%
Dividend payout	100.0%	101.0%	101.0%	119.0%	97.0%	119.0%

Source: Inve data · annual ratios · to Mar 2026

What the price assumes

Growth trap

To justify its price of ₹1603, this stock must grow earnings at 18% every year for 5 years. Our analysis caps realistic growth at ~3%. At that growth it is worth ₹812 — downside of 49%.

Growth the price implies: 18.1% a year; for 5 years, fading to 4%
It has actually compounded at: 8.2% a year; net profit, FY23–FY26 · EPS 8.2%
The gap: 0.2 pp; -49% downside if it only repeats history

Price today ₹1,603.4 Value at the reference growth ₹812.28

Why this baseline, and what it is built on

Colgate-Palmolive's financial performance shows a concerning trend, with the last three reported quarters (2025-Q1, Q2, Q3) exhibiting year-over-year declines in both sales and net profit, despite earlier strong growth. While management has a good promise track record ('new' and 'on_track' only) and provides positive guidance on margin maintenance, village reach, and premiumization growth, the recent negative financial results contradict these optimistic outlooks. A conservative initial growth rate of 3% is assigned, acknowledging the strong brand and potential for recovery, but heavily discounting aggressive growth targets until a clear turnaround is evident in the financials. The low leverage and stable industry support a lower discount rate, but recent performance dips reduce confidence.

— Sales growth was strong (10-13%) until 2024-Q2, but declined YoY in 2025-Q1 (-1.81%), 2025-Q2 (-4.14%), and 2025-Q3 (-6.0%).
— TTM Net Profit growth slowed significantly from 26.4% (ending 2024-Q1) to 8.5% (ending 2025-Q1), and recent quarters show YoY declines.
— Promise track record: 2 'new', 3 'on_track', with no 'ghosted' or 'missed' promises.
— Guidance includes maintaining EBITDA margins (32-34%), '2x the number of villages', and '4x premiumization growth'.
— Balance sheet leverage (Borrowings/Reserves) is ~0.04.
— Management notes 'urban (bottom 70%) demand will also pick up... particularly towards the back half of this year', implying current weakness.

Through 2025-12-31

Change the assumptions yourself in the DCF tool →

Ownership

Who owns it

Promoters hold 51.00% as of Sept 2026; institutions added 0.02 pts since Jun 2026.

Promoters 0.00 pts 51.00%
Foreign institutions +0.11 pts 13.71%
Domestic institutions −0.09 pts 15.45%
Government −0.28 pts 0.00%
Public +0.25 pts 19.82%

3,29,953 shareholders on the register.

Source: Exchange shareholding filings · to Sept 2026 · 8 filings held

Who was buying across the market this quarter

Who bought this quarter

since Jun 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

Insurer newly disclosed 5.39% held
newly disclosed 2.61% held
Mutual fund newly disclosed 2.20% held

The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.

Who is on the register

Named in the Sep 2026 filing

Every holder of Colgate Palmolive (India) Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	40.06%	unchanged
	10.94%	unchanged
Insurer	5.39%	newly disclosed
	2.61%	newly disclosed
Mutual fund	2.20%	newly disclosed
Insurer	—	off the list
Mutual fund	—	off the list
Mutual fund	—	off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in COLPAL

Filings to Sep 2026

1 new, 7 added, 9 trimmed, 3 sold out — net +1.56 L shares (+1.1%).

Held by funds: ₹2.5k Cr; 28 schemes
Biggest holder: SBI Large and Midcap Fund; ₹734 Cr · 1.8% of that fund

Scheme	Holding	Last month	Held since
SBI Large and Midcap Fund SBI Mutual Fund	₹734 Cr	held	May '25
Nippon India Multi Cap Fund Nippon India Mutual Fund	₹483 Cr	+6.83 L	Aug '23
SBI Midcap Fund SBI Mutual Fund	₹317 Cr	held	Apr '25
Nippon India Large Cap Fund Nippon India Mutual Fund	₹280 Cr	held	Jul '23
Nippon India Growth Mid Cap Fund Nippon India Mutual Fund	₹229 Cr	held	Oct '25
HDFC Mid Cap Fund HDFC Mutual Fund	₹187 Cr	held	Jan '25
SBI Consumption Opportunities Fund SBI Mutual Fund	₹84 Cr	held	Aug '23
SBI Multi Asset Allocation Fund SBI Mutual Fund	₹53 Cr	held	Apr '25

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Sep 2026

7 added, 9 trimmed — net +1.56 L shares (+1.1%)

Funds are sitting on: -28%; vs est. average cost
Held by funds: ₹2.5k Cr; 28 schemes · ≈ 5.3% of the company
Biggest holder: SBI Large and Midcap Fund; ₹734 Cr · 1.8% of that fund
Longest holder: Nippon India ETF Nifty Dividend Opportunities 50; 12y 6m · since Apr '14

Shares held by these funds +245%

Oct '23 1.44 cr shares Sep '26

Your own record

Start an Inve Case for Colgate Palmolive (India) Limited

Free account: one company. Everything above stays public.

Write why you follow Colgate Palmolive (India) Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Fast Moving Consumer Goods companies

All Fast Moving Consumer Goods companies → · Fast Moving Consumer Goods earnings growth →

Learn to analyse Colgate Palmolive (India) Limited

Guides on how to read this kind of business and the numbers that matter.